GateHouse Bio (fka sRNAlytics)

We believe there is an RNA code that drives every disease

United States · Founded 2016 · $5.7M raised

Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$5.7M
Last Round
$5.5M Series AApr 2018
Rounds
2

About

GateHouse Bio is a TechBio company that uses AI to decode small RNA (sRNA) isoforms and develop biomarker-guided precision oligonucleotide therapeutics. Its proprietary Code-Breaker™ platform digitally designs targeted therapies for pulmonary, cardiac, neurological, and autoimmune diseases. The company seeks research collaborators, biopharma partners, and investors to advance its lead programs into human clinical trials.

Summary

GateHouse Bio (fka sRNAlytics) is a Biotech company based in United States, founded in 2016. It has raised $5.7M in total across 2 rounds, most recently a $5.5M Series A round in Apr 2018. Investors include SOSV, IndieBio and Claritas Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed RoundApr 2018
$250K

Sign up to see all 2 rounds

Series A through Seed — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

GateHouse Bio (fka sRNAlytics) on Indexed.vc
<a href="https://indexed.vc/companies/gatehouse-bio-fka-srnalytics"><img src="https://indexed.vc/api/badge/company/gatehouse-bio-fka-srnalytics" alt="GateHouse Bio (fka sRNAlytics) on Indexed.vc" width="260" height="76" /></a>